NCT05466812

Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Efficacy Evaluation of Strontium-89 Chloride for Differentiated Thyroid Cancer With Bone Metastases

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Detailed description

Using biochemical markers (such as thyroglobulin), functional markers (such as change of tumor-background ratio on bone scan), etc to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.

Conditions

• Thyroid Neoplasm Follicular
• Bone Metastases

Interventions

Type	Name	Description
DRUG	Sr-89	1. strontium-89 chloride treatment 2. periodical evaluation and follow-up

Timeline

• Start date: 2022-07-13
• Primary completion: 2024-07-13
• Completion: 2025-07-13
• First posted: 2022-07-20
• Last updated: 2022-07-20

Locations

1 site across 1 country: China